164 related articles for article (PubMed ID: 6409012)
21. [Diagnosis of amelanotic malignant melanoma by means of the fluorescence method (Falck & Hillarp) and determination of 5-S-cysteinyldopa in the lesions].
Morishima T; Fukada E; Nagashima N
Nihon Hifuka Gakkai Zasshi; 1983 Jan; 93(1):51-4. PubMed ID: 6408288
[No Abstract] [Full Text] [Related]
22. [Excretion of 5-S-cysteinyldopa in the urine of Japanese patients with malignant melanoma--a helpful biochemical marker for assessing the progression of disease].
Hanawa S
Nihon Hifuka Gakkai Zasshi; 1983 Mar; 93(4):433-42. PubMed ID: 6411952
[No Abstract] [Full Text] [Related]
23. [Urinary 5-S-cysteinyldopa levels in patients with malignant melanoma. Preliminary results].
Césarini JP; Meunier M
Rev Prat; 1975 Nov; 25(51):4037-9. PubMed ID: 1209143
[No Abstract] [Full Text] [Related]
24. Quantitative determination of 5-S-cysteinyldopa, dopa and dopamine in the urine by means of high-performance liquid chromatography. A comparison with data obtained by means of fluorometry.
Morishima T; Saito M; Hanawa S
J Dermatol; 1981 Aug; 8(4):301-4. PubMed ID: 6795251
[No Abstract] [Full Text] [Related]
25. Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
Graef V; Paul E
Br J Dermatol; 1982 Jan; 106(1):53-7. PubMed ID: 6800394
[TBL] [Abstract][Full Text] [Related]
26. 5-S-cysteinyldopa, dopa, and dopamine in the kidney and some other tissues.
Agrup G; Hansson C; Rorsman H; Rosengren E
Acta Derm Venereol; 1980; 60(1):63-4. PubMed ID: 6153836
[TBL] [Abstract][Full Text] [Related]
27. Urinary excretion of 5-S-cysteinyldopa in healthy Japanese.
Morishima T; Hanawa S
Acta Derm Venereol; 1981; 61(2):149-50. PubMed ID: 6165192
[TBL] [Abstract][Full Text] [Related]
28. Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases.
Yamada K; Walsh N; Hara H; Jimbow K; Chen H; Ito S
Arch Dermatol; 1992 Apr; 128(4):491-4. PubMed ID: 1580656
[TBL] [Abstract][Full Text] [Related]
29. 5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid.
Agrup G; Andersson T; Falck B; Persson K; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1975; 55(1):5-6. PubMed ID: 46673
[TBL] [Abstract][Full Text] [Related]
30. Dopaquinone addition products in cultured human melanoma cells.
Carstam R; Hansson C; Lindbladh C; Rorsman H; Rosengren E
Acta Derm Venereol; 1987; 67(2):100-5. PubMed ID: 2438872
[TBL] [Abstract][Full Text] [Related]
31. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
Sameshima T; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
[TBL] [Abstract][Full Text] [Related]
32. 5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations.
Aubert C; Rosengren E; Rorsman H; Rouge F; Foa C; Lipcey C
Eur J Cancer (1965); 1977 Nov; 13(11):1299-308. PubMed ID: 590287
[No Abstract] [Full Text] [Related]
33. Trichochromes in the urine of melanoma patients.
Agrup G; Lindbladh C; Prota G; Rorsman H; Rosengren AM; Rosengren E
J Invest Dermatol; 1978 Feb; 70(2):90-1. PubMed ID: 621413
[TBL] [Abstract][Full Text] [Related]
34. Automated high-performance liquid chromatographic determination of 5-S-cysteinyl-3,4-dihydroxyphenylalanine in urine.
Kågedal B; Källberg M; Arstrand K; Hansson C
J Chromatogr; 1989 Jul; 473(2):359-70. PubMed ID: 2504759
[TBL] [Abstract][Full Text] [Related]
35. Analysis of cysteinyldopas, dopa, dopamine, noradrenaline and adrenaline in serum and urine using high-performance liquid chromatography and electrochemical detection.
Hansson C; Agrup G; Rorsman H; Rosengren AM; Rosengren E; Edholm LE
J Chromatogr; 1979 Jan; 162(1):7-22. PubMed ID: 33194
[TBL] [Abstract][Full Text] [Related]
36. [Definitive diagnosis of early malignant melanoma lesions by the quantitative analysis of 5-S-cysteinyldopa in the tissue and touch fluorescence method].
Kanematsu S; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 Jun; 99(7):783-91. PubMed ID: 2511360
[TBL] [Abstract][Full Text] [Related]
37. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
38. The quantitative determination of 5-S-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high-pressure liquid chromatography.
Hansson C; Edholm LE; Agrup G; Rorsman H; Rosengren AM; Rosengren E
Clin Chim Acta; 1978 Sep; 88(3):419-27. PubMed ID: 699334
[TBL] [Abstract][Full Text] [Related]
39. The effect of cysteine on oxidation of tyrosine, dopa, and cysteinyldopas.
Agrup G; Hansson C; Rorsman H; Rosengren E
Arch Dermatol Res; 1982; 272(1-2):103-15. PubMed ID: 6819815
[TBL] [Abstract][Full Text] [Related]
40. Glutathionedopa in malignant melanoma.
Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1977; 57(3):221-2. PubMed ID: 71825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
